Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Pivotal data are expected soon on tezepelumab, Amgen and Astrazeneca's shot at non-eosinophilic asthma.
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.